Heparinoid Market Size is predicted to record a 6.6% CAGR during the forecast period for 2023-2031.
Heparinoid is an anti-thrombotic medication that decreases swelling in the veins just under the skin and helps to prevent the formation of tiny blood clots. To alleviate bruising, heparinoid is prescribed. Superficial thrombophlebitis causes internal bruising (haematoma) or inflamed veins close to the skin's surface due to tiny blood clots. Heparin is a popular injectable anticoagulant to stay alive during surgical procedures and avoid blood clots in the veins and arteries. This is also used for diagnosing and treating thromboembolisms of the lungs, veins, and arteries. The blood-clotting protein heparin originates from dead animals' flesh and blood vessels. An increasing number of people suffering from long-term blood disorders is anticipated to contribute to the global market for antiplatelet medications. The rising occurrence of chronic disorders, including cardiovascular diseases, is propelling the industry. The rising incidence of heart disease is a major contributor, propelling the market for antiplatelet medicines. Furthermore, the prevalence of chronic diseases, especially cardiovascular disorders, among the elderly may increase the market for heparin medications worldwide.
However, the market growth is hampered by the high-cost criteria for the safety and health of the heparinoid market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity because herparin medications are known to have a high price tag, which could slow down the market's expansion. Some herparin medications have safety, effectiveness, and tolerability limits, and developing economies often lack adequate healthcare infrastructure. All of these things are bad for the world's pharmaceutical market. In addition, the prevalence of fake medications and adverse reactions to antiplatelet medications are anticipated to hamper the market's expansion in the years to come.
Competitive Landscape
Some Major Key Players In The Heparinoid Market:
- Merck KGaA
- SEIKAGAKU CORPORATION
- TSI Group Ltd.
- Synutra Pure, Ltd.
- Bioiberica S.A.U.
- Kala Health Inc.
- Beloorbayir Biotech Ltd
- Sichuan Biosyn Pharmaceutical Co., Ltd
- Seikagaku Corporation
- Jiaxing Hengjie Bio-pharmaceutical LLC
- Wright Health
- Bioiberica
- Manus Aktteva Biopharma
- Pfizer
- Hepac
- Smithfield Foods
- Huaxi Biological
- Accredited Consultants
- Techdow Pharmaceutical
- Haipurui Pharmaceutical
- Fresenius
- Qianhong Biopharmaceutical
- Dongcheng Biochemical
- Jinyou Biochemical Pharmaceutical
- Changshan Biochemical Pharmaceutical
- LDO
- Opocrin
- Gland Pharma
- Scientific Protein Lab
- Sandoz
- Others
Market Segmentation:
The global heparinoid market is segmented based on raw material, application, and dosage form. As per the raw material, the market is segmented into chondroitin sulphates, dermatan sulphate, and heparin sulphate. The application segment comprises pharmaceutical, dietary supplements, sports nutrition, animal feed, and others. By dosage form, the market is segmented into powder and capsule.
Based On The Raw Material, The Chondroitin Sulphates Global Heparinoid Market Segment Is Accounted As A Major Contributor To The Global Heparinoid Market.
The chondroitin sulphates heparinoid market is expected to lead with a major global market share in 2022. The conditions of osteoarthritis and cataracts are treated with chondroitin sulfate. Combinations with hyaluronic acid, collagen peptides, glucosamine, and manganese ascorbate are common. There is a plethora of additional medical uses for chondroitin sulfate.
Sports Nutrition Segment To Witness Growth At A Rapid Rate.
The sports nutrition industry makes up the bulk of heparinoid usage because proper sports nutrition is essential for athletes to function at a high level. This nutrition plan was developed with athletes and active people in mind so they may perform at their best. The right food, energy, nutrients, and fluids are supplied so the body can function optimally.
In The Region, The North American Global Heparinoid Market Holds A Significant Revenue Share.
The North American global heparinoid market is expected to record the maximum market revenue share in the near future. It can be attributed to a rising need for disease-specific treatments and a rising use of modern technology. The market's growth rate within the region would be further accelerated by the increasing presence of major key players and rising healthcare expenditure. In addition, Asia Pacific is estimated to grow rapidly in the global heparinoid market because of a dramatic increase in healthcare spending, a large pool of prospective patients, and the rise in demand for technologically advanced products.
Recent Developments:
- In October 2023, Seikagaku Corporation ("Seikagaku") announced positive findings from additional research in the United States for their lumbar disc herniation treatment, SI-6603, also known as Condoliase.
Heparinoid Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 6.6 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Raw material, Application, Dosage Form |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Merck KGaA, SEIKAGAKU CORPORATION, TSI Group Ltd., Synutra Pure, Ltd., Bioiberica S.A.U., Kala Health Inc., Beloorbayir Biotech Ltd, Sichuan Biosyn Pharmaceutical Co., Ltd, Seikagaku Corporation, and Jiaxing Hengjie Bio-pharmaceutical LLC. Wright Health, Bioiberica, Manus Aktteva Biopharma, Pfizer, Hepac, Smithfield Foods, Huaxi Biological, Accredited Consultants, Techdow Pharmaceutical, Haipurui Pharmaceutical, Fresenius, Qianhong Biopharmaceutical, Dongcheng Biochemical, Jinyou Biochemical Pharmaceutical, Changshan Biochemical Pharmaceutical, LDO, Opocrin, Gland Pharma, Scientific Protein Lab, Sandoz, Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
